This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Subscribe To Our Newsletter & Stay Updated